Association Between the Pretreatment S-VEGF Level and Nine Clinicopathological Factors in Non-Hodgkin's Lymphoma
| Factor . | No. of Cases . | S-VEGF* . | P . | |
|---|---|---|---|---|
| . | . | 228 pg/mL N (%) . | >228 pg/mL N (%) . | . |
| WHO performance status | ||||
| 0-1 | 67 | 39 (58%) | 28 (42%) | |
| 2-4 | 15 | 2 (13%) | 13 (87%) | .002 |
| International Prognostic Index | ||||
| 0-2 | 57 | 34 (60%) | 23 (40%) | .003 |
| 3-4 | 22 | 5 (23%) | 17 (77%) | |
| Serum LDH level | ||||
| Normal | 53 | 32 (60%) | 21 (40%) | .005 |
| > Normal | 26 | 7 (27%) | 19 (73%) | |
| Gender | ||||
| Male | 38 | 23 (61%) | 15 (39%) | .08 |
| Female | 44 | 18 (41%) | 26 (59%) | |
| Age at diagnosis | ||||
| ≤60 | 42 | 22 (52%) | 20 (48%) | .66 |
| >60 | 40 | 19 (48%) | 21 (52%) | |
| No. of extranodal sites | ||||
| ≤0-1 | 74 | 38 (51%) | 36 (49%) | .71 |
| >1 | 8 | 3 (38%) | 5 (63%) | |
| Presence of B-symptoms | ||||
| No | 67 | 33 (49%) | 34 (51%) | .78 |
| Yes | 15 | 8 (53%) | 7 (47%) | |
| Histological grade | ||||
| Low | 18 | 10 (56%) | 8 (44%) | .82 |
| Intermediate | 40 | 20 (50%) | 20 (50%) | |
| High | 22 | 10 (45%) | 12 (55%) | |
| Ann Arbor stage | ||||
| I | 22 | 10 (45%) | 12 (55%) | .85 |
| II | 24 | 11 (46%) | 13 (54%) | |
| III | 14 | 8 (57%) | 6 (43%) | |
| IV | 22 | 12 (55%) | 10 (45%) | |
| Factor . | No. of Cases . | S-VEGF* . | P . | |
|---|---|---|---|---|
| . | . | 228 pg/mL N (%) . | >228 pg/mL N (%) . | . |
| WHO performance status | ||||
| 0-1 | 67 | 39 (58%) | 28 (42%) | |
| 2-4 | 15 | 2 (13%) | 13 (87%) | .002 |
| International Prognostic Index | ||||
| 0-2 | 57 | 34 (60%) | 23 (40%) | .003 |
| 3-4 | 22 | 5 (23%) | 17 (77%) | |
| Serum LDH level | ||||
| Normal | 53 | 32 (60%) | 21 (40%) | .005 |
| > Normal | 26 | 7 (27%) | 19 (73%) | |
| Gender | ||||
| Male | 38 | 23 (61%) | 15 (39%) | .08 |
| Female | 44 | 18 (41%) | 26 (59%) | |
| Age at diagnosis | ||||
| ≤60 | 42 | 22 (52%) | 20 (48%) | .66 |
| >60 | 40 | 19 (48%) | 21 (52%) | |
| No. of extranodal sites | ||||
| ≤0-1 | 74 | 38 (51%) | 36 (49%) | .71 |
| >1 | 8 | 3 (38%) | 5 (63%) | |
| Presence of B-symptoms | ||||
| No | 67 | 33 (49%) | 34 (51%) | .78 |
| Yes | 15 | 8 (53%) | 7 (47%) | |
| Histological grade | ||||
| Low | 18 | 10 (56%) | 8 (44%) | .82 |
| Intermediate | 40 | 20 (50%) | 20 (50%) | |
| High | 22 | 10 (45%) | 12 (55%) | |
| Ann Arbor stage | ||||
| I | 22 | 10 (45%) | 12 (55%) | .85 |
| II | 24 | 11 (46%) | 13 (54%) | |
| III | 14 | 8 (57%) | 6 (43%) | |
| IV | 22 | 12 (55%) | 10 (45%) | |
Abbreviations: S-VEGF, serum vascular endothelial growth factor; WHO, World Health Organization; LDH, lactate dehydrogenase.
The median was used as the cut-off value